Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nephrocalcinosis20.04.01.0010.000052%Not Available
Nephropathy toxic20.05.03.002; 12.03.01.0100.000070%Not Available
Nephrotic syndrome20.05.01.0020.000419%
Neuralgia17.02.07.0050.000070%
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutrophilia01.02.01.0050.000122%Not Available
Night sweats23.02.03.006; 08.01.03.0310.000129%Not Available
Nitrogen balance negative13.13.01.010--Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.0010.000052%Not Available
Nystagmus06.05.02.006; 17.02.02.0060.000035%
Obesity14.03.02.0090.000052%
Obsessive-compulsive disorder19.06.05.0020.000070%Not Available
Ocular hypertension06.03.01.0030.000105%Not Available
Odynophagia07.01.06.0360.000035%Not Available
Oedema08.01.07.006; 14.05.06.0100.000472%Not Available
Oesophageal perforation07.04.05.0010.000052%
Oesophageal varices haemorrhage24.07.02.022; 09.01.06.004; 07.12.01.0030.000035%
Oesophagitis07.08.05.0010.000035%
Oligohydramnios18.05.01.0010.000157%Not Available
Oliguria20.01.03.0040.000087%Not Available
Optic neuritis17.04.05.001; 06.04.08.002; 10.02.01.0970.000087%Not Available
Osteoarthritis15.01.04.0010.000245%Not Available
Osteochondrosis15.07.03.0020.000087%Not Available
Osteolysis14.04.04.006; 15.02.03.0080.000035%Not Available
Osteonecrosis24.04.05.004; 15.02.04.0070.001031%
Osteoporosis14.04.04.002; 15.02.03.0020.001276%
Osteoporotic fracture15.08.02.007; 14.04.04.007; 12.04.02.0050.000280%Not Available
Osteosclerosis15.02.04.0120.000035%Not Available
Otorrhoea04.03.01.0120.000035%Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene